ATHOS-3 Trial

Q: In the recently published ATHOS-3 trial, which of the following drug has shown a promising value in the treatment of 'high output vasodilatory shock'?

A) Vitamin C
B) Hydrocortisone
C) pRBC (blood)
D) Angiotensin II
E) Phenylephrine


Answer: D

Angiotensin II is the new sensation! In the recently published trial - ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock), which randomized 321 patients (163 received angiotensin II, and 158 received placebo), the primary endpoint was reached by more patients in the angiotensin II group (114 of 163 patients, 69.9%) than in the placebo group (37 of 158 patients, 23.4%) (odds ratio, 7.95; 95% confidence interval [CI], 4.76 to 13.3; P < 0.001).

The primary endpoint was a response with respect to mean arterial pressure (MAP) at hour 3 after the start of infusion, with response defined as an increase from baseline of at least 10 mm Hg or an increase to at least 75 mm Hg, without an increase in the dose of background vasopressors.


Read abstract at link with reference

Reference:

Khanna A et al. "Angiotensin II for the Treatment of Vasodilatory Shock". New Engl J Med. 2017. 377:419-30. :: http://www.nejm.org/doi/full/10.1056/NEJMoa1704154